eXoZymes CEO to Discuss Commercialization, Key Milestones, and Potential Catalysts in Fireside Chat with Water Tower Research
Key Highlights
- ➤eXoZymes CEO to outline NCT commercialization strategy in October 22 fireside chat
- ➤NCT manufacturing economics and productivity improvements will be discussed with investors
- ➤Curia partnership is expected to support NCT commercial-scale production
- ➤NCTx could create revenue streams focused on NCT applications
- ➤Company will discuss funding, milestones, and potential catalysts over the next 12 months
Expert Statements
Michael Heltzen, CEO of eXoZymes
“Our mission at eXoZymes is to turn scientific breakthroughs into real-world products and commercial opportunities. Nature has already invented an extraordinary wealth of valuable molecules, but many have remained inaccessible because nobody could manufacture them at the quantities, purity, or cost needed to bring them to market. By combining AI with our cell-free biomanufacturing platform, we believe we can change that. NCT is our first opportunity to demonstrate this potential, but our ambition extends far beyond a single molecule.”
Michael Heltzen, CEO of eXoZymes
“What makes our business model particularly exciting is that we don't need to build and operate large manufacturing facilities to pursue these opportunities. Instead, we can focus our resources on what we do best: developing new molecules and manufacturing processes, while working with partners to scale production and bring products to market. As we advance NCT toward commercialization, we're also building the foundation for a repeatable engine of innovation that could unlock entirely new opportunities in nutraceuticals and pharmaceuticals. I look forward to discussing our progress, strategy, and the milestones ahead during the fireside chat.”
LOS ANGELES, CA / ACCESS Newswire / October 21, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced that Chief Executive Officer, Michael Heltzen, will participate in a fireside chat hosted by Water Tower Research ("WTR") tomorrow, Thursday, October 22, 2026, at 11AM Eastern / 8AM Pacific Time.
Moderated by Robert Sassoon, Managing Director of Healthcare, Emerging Growth & Special Situations at WTR, the discussion will focus on how eXoZymes intends to translate its cell-free biomanufacturing technology into commercial opportunities, beginning with NCT - a rare naturally occurring molecule being developed for nutraceutical applications and longer-term pharmaceutical opportunities.
Get started
Create a free account to read the full story.